The largest operating expense was General & Administrative costs, amounting to US$2.90b (79% of total expenses). Explore how ...

Stephen A. Smith is a popular sports Pundit and media personality. His bold takes on sports, entertainment and pop culture on ...

UBS downgraded Smith & Nephew to Neutral from Buy with an unchanged price target of 1,250 GBp. The company’s near-term earnings momentum ...

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will showcase the latest ...

Smith+Nephew announced today that it aims to develop technology in a new field of arthroscopic surgical innovation.

Learn more by visiting the CORIOGRAPH webpage here. To learn more about Smith+Nephew’s advanced solutions for Orthopaedic Reconstruction, please visit our booth (#3729) at the American Academy ...

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, is pleased to announce that the latest annual report from the Australian Orthopaedic Association National Joint Replacement ...

Smith+Nephew submitted its TESSA System for FDA 510 (k) clearance, according to a March 4 news release. TESSA, which stands for Tracking Enabled Spatial Surgery Assistant, is pending FDA clearance for ...

Smith+Nephew continues to pioneer in Sports Medicine and is excited to introduce a new category called Spatial Surgery - a revolutionary new frontier in arthroscopic surgical innovation.

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will feature the latest advancements in Orthopaedic Reconstruction at the American Academy of Orthopaedic ...

Smith+Nephew's CARTIHEAL AGILI-C Cartilage Repair Implant is an FDA approved device that was previously granted breakthrough designation and is now evolving the cartilage repair landscape. The unique ...

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will feature the latest advancements in Orthopaedic Reconstruction at the American Academy of Orthopaedic Sur ...